Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort

Conclusion CYP2D6 variation appeared not to be a good pharmacogenetic marker for predicting risperidone-related ADRs in this naturalistic South African cohort. Evaluation of a larger cohort would be needed to confirm these observations, including an examination of the role of potential intermediaries between the hypothesised genetic and clinical phenotypes.
Source: Applied and Translational Genomics - Category: Genetics & Stem Cells Source Type: research